Abrdn Life Sciences Investors (NYSE: HQL)
Financials · Capital Markets · US
$18.15
+2.66% today · +12.2% 1Y
Abrdn Life Sciences Investors (NYSE: HQL) operates in the Capital Markets industry within the Financials sector. The company is valued at $551.91M.
Over the last twelve months the share price has gained 12.2%, trading between 15.66 and 22.67.
Tweenvest scores Abrdn Life Sciences Investors across four factors: quality 49/100, value 41/100, dividend 70/100. Its strongest factor is dividend.
HQL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $551.91M
- Revenue (TTM)
- $1.11M
- P/E
- 2.79
- EPS
- 6.52
- Dividend yield
- 10.03%
- Beta (5Y)
- 0.73
- 52-week high
- $22.67
- 52-week low
- $15.66
- Avg volume (3M)
- —
- Shares outstanding
- 30.41M
- Employees
- —
- Next earnings
- —
About Abrdn Life Sciences Investors
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
- ISIN
- US87911K1007
- Founded
- 1992
- Listed since
- May 1, 1992
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Capital Markets companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nuveen California AMT-Free Quality Municipal Income FundNYSE: NKX | $559.56M | $10.47 | -0.57% |
| Barita Investments LimitedJMSE: BIL | $555.07M | J$73.50 | -10.37% |
| PT Indokripto Koin Semesta TbkIDX: COIN | $554.74M | Rp675.00 | -7.53% |
| GAMCO Investors, Inc.OTCPK: GAMI | $553.05M | $25.75 | +2.96% |
| Invesco Exchange-Traded Fund Trust - Invesco Pharmaceuticals ETFARCA: PJP | $548.04M | $122.88 | +1.65% |
| AURELIUS Equity Opportunities SE & Co. KGaAHMSE: AR4 | $547.73M | €660.00 | +5.60% |
| iShares Trust - iShares U.S. Digital Infrastructure and Real Estate ETFARCA: IDGT | $547.68M | $120.37 | +4.40% |
| Sky Constant Century Inc.OTCPK: SKYC | $546.47M | $— | — |
Figures last refreshed Oct 4, 2026.